We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ASLAN Selects PharmaNet/i3 as Strategic Partner for Oncology Development


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ASLAN Selects PharmaNet/i3 as Strategic Partner for Oncology Development"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

PharmaNet/i3 has announced that ASLAN Pharmaceuticals has selected PharmaNet/i3 as a Strategic Partner supporting the development of their oncology portfolio in Asia, and conducting Phase I and Phase II clinical trials for two of ASLAN’s compounds.

Dr. Alan Barge, ASLAN’s Chief Medical Officer, stated, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNet/i3, a company that shares our focus on quality and efficiency.”

PharmaNet/i3 has been conducting clinical studies for innovative oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments.

The Company has extensive experience in the development of a variety of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines.

More than four hundred local, regional and global oncology clinical trials have been awarded to PharmaNet/i3 in the past five years, including more than a dozen registration programs, seven of which resulted in NDA/MAA approvals.

“Clinical development of oncology therapeutics requires a special understanding of the mechanism of action and the different approaches to cancer therapies,” commented Dalvir Gill, PhD, President, Phase II – IV Development, PharmaNet/i3.

Gill continued, “ASLAN has a novel and creative approach to personalized medicine and combination therapy. We will work closely with ASLAN to address the unique methodologies needed to evaluate the efficacy and safety of their innovative products and look forward to a long and productive relationship.”

Advertisement